The combination of bendamustine, bortezomib, and dexamethasone was reported to be effective in achieving overall response rates in myeloma.
While women who lost more than 5 kg after age 18 were at a 23% reduced risk for breast cancer, those who gained more than 30 kg were at a 32% increased risk.
The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."
Scientists are testing immune checkpoint proteins, CD8 T cell clonal expansion, mutational load, and PSA levels as predictive biomarkers for prostate cancer immunotherapy outcomes.
Smoking cessation may improve survival regardless of the type of cancer diagnosed, due to a reduction in comorbidities.
Despite the success of targeted therapy in other cancers, targeted therapy has failed to improve outcomes in triple-negative breast cancer.
Selinexor represents a much-needed therapeutic addition to the available agents for the treatment of heavily pre-treated patients with few options.
Recent discoveries of germline mutations are driving research in novel treatments, including immunotherapies, for prostate cancer.
SN-MMR was strongly associated with OS, melanoma-specific survival, and DFS among patients with a positive sentinel node biopsy.
Researchers are making progress in the search for biomarkers that can help identify which patients are most likely to benefit from radiotherapy.
If a patient develops any adverse event while on ponatinib, clinicians should perform a risk-benefit analysis before deciding whether to continue treatment.
Rarely, patients with prostate cancer will develop metastases to the gastrointestinal tract, which limit treatment options.
TKIs offer the possibility of durable responses for patients with CML, though it is unclear whether discontinuation is feasible.
According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.
A recent review suggests that cisplatin-etoposide and carboplatin-paclitaxel regimens are comparable in efficacy.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Are Feasible
- Navigating the Costs of Chronic Myeloid Leukemia: A Glimpse Into the Future
- NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib